Los Angeles Capital Management LLC Purchases 364,986 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Los Angeles Capital Management LLC raised its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 66.0% in the 4th quarter, HoldingsChannel reports. The fund owned 918,391 shares of the company’s stock after purchasing an additional 364,986 shares during the period. Los Angeles Capital Management LLC’s holdings in Neurocrine Biosciences were worth $121,007,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently modified their holdings of the company. DSM Capital Partners LLC lifted its holdings in shares of Neurocrine Biosciences by 15.4% during the 3rd quarter. DSM Capital Partners LLC now owns 1,224,017 shares of the company’s stock worth $137,702,000 after acquiring an additional 163,747 shares during the period. Braidwell LP boosted its position in Neurocrine Biosciences by 3.7% in the third quarter. Braidwell LP now owns 968,024 shares of the company’s stock valued at $108,903,000 after buying an additional 34,662 shares in the last quarter. Jacobs Levy Equity Management Inc. grew its stake in Neurocrine Biosciences by 59.0% during the third quarter. Jacobs Levy Equity Management Inc. now owns 692,374 shares of the company’s stock worth $77,892,000 after buying an additional 256,920 shares during the last quarter. Westfield Capital Management Co. LP increased its holdings in shares of Neurocrine Biosciences by 73.0% during the third quarter. Westfield Capital Management Co. LP now owns 649,292 shares of the company’s stock worth $73,045,000 after buying an additional 273,952 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Neurocrine Biosciences by 3.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 623,267 shares of the company’s stock worth $70,118,000 after acquiring an additional 18,334 shares in the last quarter. Institutional investors own 92.59% of the company’s stock.

Insider Buying and Selling at Neurocrine Biosciences

In other Neurocrine Biosciences news, Director Richard F. Pops sold 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $132.47, for a total transaction of $1,987,050.00. Following the completion of the transaction, the director now owns 29,512 shares of the company’s stock, valued at approximately $3,909,454.64. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other Neurocrine Biosciences news, insider David W. Boyer sold 1,328 shares of Neurocrine Biosciences stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $135.41, for a total value of $179,824.48. Following the completion of the transaction, the insider now directly owns 4,895 shares of the company’s stock, valued at approximately $662,831.95. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Richard F. Pops sold 15,000 shares of the company’s stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $132.47, for a total value of $1,987,050.00. Following the sale, the director now owns 29,512 shares of the company’s stock, valued at $3,909,454.64. The disclosure for this sale can be found here. Insiders have sold 181,547 shares of company stock valued at $25,039,887 in the last 90 days. 4.30% of the stock is currently owned by company insiders.

Neurocrine Biosciences Trading Down 0.3 %

Shares of NASDAQ:NBIX traded down $0.37 during trading on Thursday, hitting $142.66. 394,208 shares of the company’s stock traded hands, compared to its average volume of 850,797. The company has a 50-day moving average price of $137.11 and a 200-day moving average price of $128.51. Neurocrine Biosciences, Inc. has a 52 week low of $89.04 and a 52 week high of $148.37. The company has a market cap of $14.20 billion, a price-to-earnings ratio of 58.94 and a beta of 0.28.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings results on Wednesday, February 7th. The company reported $1.44 earnings per share for the quarter, beating the consensus estimate of $1.13 by $0.31. The company had revenue of $515.20 million during the quarter, compared to analysts’ expectations of $518.52 million. Neurocrine Biosciences had a net margin of 13.23% and a return on equity of 12.85%. The business’s quarterly revenue was up 25.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.88 earnings per share. On average, analysts predict that Neurocrine Biosciences, Inc. will post 4.8 earnings per share for the current fiscal year.

Analyst Ratings Changes

NBIX has been the subject of several research analyst reports. BMO Capital Markets lifted their price objective on Neurocrine Biosciences from $129.00 to $138.00 and gave the company a “market perform” rating in a research report on Thursday. Wells Fargo & Company raised shares of Neurocrine Biosciences from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $140.00 to $170.00 in a report on Wednesday, April 24th. JPMorgan Chase & Co. boosted their target price on shares of Neurocrine Biosciences from $148.00 to $158.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 20th. Needham & Company LLC reissued a “hold” rating on shares of Neurocrine Biosciences in a research note on Wednesday. Finally, HC Wainwright boosted their price objective on shares of Neurocrine Biosciences from $150.00 to $160.00 and gave the stock a “buy” rating in a research report on Thursday. Six research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Neurocrine Biosciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $145.83.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.